Magic Mushrooms Are Giving Investors a Bad Trip
Companies have raised hundreds of millions of dollars to fund research into psychedelics, but they still need to demonstrate they have a viable business model.
It’s been a trip.
Photo: iStock; China Photos; Drew Angerer/Getty Images. Illustration by Lara Williams.
Convincing friends who were contemplating an expensive divorce to try psychedelic drug therapy may have been the most valuable financial advice that billionaire German investor Christian Angermayer ever gave, he told an audience of finance and tech peers recently. It won’t be long before politicians trip together to resolve their differences, he says.
When not championing psychedelics’ therapeutic effects (occasionally with actress friend Uma Thurman), Angermayer tries to consume them himself once a year (only where they’re legal). He’s even convinced his parents to partake.